Clinical Trial Update: An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function [Phase 1]

View source ↗

Summary

Open-label Phase 1 study evaluating pharmacokinetics and safety of HALAVEN (eribulin mesylate) in adults with cancer and impaired renal function; the trial has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Halaven (eribulin)

Snippet

Sponsor: Eisai Inc. | Conditions: Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Status: COMPLETED